New study tracks Finerenone's impact on kidney risk in diabetic patients

NCT ID NCT07554469

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study will follow 500 adults with chronic kidney disease and type 2 diabetes who are taking finerenone, a drug that helps protect the kidneys and heart. Researchers want to see if a tool called the Klinrisk score, which estimates the risk of kidney disease getting worse, improves after 2 years of treatment. The study will collect data from routine doctor visits and monitor any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Many locations

    RECRUITING

    Multiple Locations, Spain